SCHEMBL1167149

SCHEMBL1167149

CC(=O)c1ccc(Cn2ccc(NC(=O)OCc3c(F)ccc(C)c3Cl)n2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.46
NPSR1 Q6W5P4 6/20 0.46
LMNA P02545 5/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 3/20 0.46
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
GAA P10253 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
EGFR P00533 1/20 0.40
CACNA1G O43497 5/20 0.38
CACNA1H O95180 5/20 0.38
CACNA1I Q9P0X4 5/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1167475 0.91 NPSR1 (0.45) SMN1; SMN2NPSR1LMNAALDH1A1HPGD
SCHEMBL1166570 0.89 NPSR1 (0.52) SMN1; SMN2NPSR1LMNAALDH1A1HPGD
SCHEMBL1166605 0.88 NPSR1 (0.47) SMN1; SMN2NPSR1LMNAALDH1A1HPGD
SCHEMBL1166083 0.87 EGFR (0.49) SMN1; SMN2NPSR1LMNAALDH1A1HPGD
SCHEMBL1166909 0.86 NPSR1 (0.40) SMN1; SMN2NPSR1LMNAALDH1A1HPGD
SCHEMBL1166275 0.85 NPSR1 (0.45) SMN1; SMN2NPSR1LMNAALDH1A1HPGD
SCHEMBL1167203 0.84 LMNA (0.48) SMN1; SMN2NPSR1LMNAALDH1A1HPGD
SCHEMBL1166373 0.84 HCRTR1 (0.45) SMN1; SMN2NPSR1LMNAALDH1A1HPGD
SCHEMBL1166172 0.84 CACNA1G (0.48) SMN1; SMN2NPSR1LMNAALDH1A1HPGD
SCHEMBL1166657 0.84 NPSR1 (0.44) SMN1; SMN2NPSR1LMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP claimed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US claimed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US claimed
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP disclosed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US disclosed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US disclosed
EP-2242743-A1 AMINOPYRAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-10-27 EP disclosed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 SMN1; SMN2 4612/4885NPSR1 578/4885LMNA 4005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.